Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial evaluating SEP-363856 in acutely psychotic schizophrenia patients, with an open-label extension; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: TERMINATED